BRIEF published on 08/27/2025 at 13:34, 1 year 2 months ago CHEPLAPHARM Reports Stable Growth in the First Half of 2025 Pharmaceutical Industry Revenue Growth Transformation Program CHEPLAPHARM Employee Expansion
PRESS RELEASE published on 08/27/2025 at 13:29, 1 year 2 months ago CHEPLAPHARM with stable business in the first half of 2025 Cheplapharm AG reports stable business performance in the first half of 2025, with revenue up by 12% and EBITDA up by 24% compared to the second half of 2024 Financial Results Transformation Program Stability Acquisition Opportunities Cheplapharm AG
BRIEF published on 06/26/2025 at 10:36, 1 year 4 months ago CHEPLAPHARM's €750M Bond Sees High Demand and Attractive Pricing Pharmaceuticals Investor Confidence Financial Flexibility Bonds CHEPLAPHARM
PRESS RELEASE published on 06/26/2025 at 10:31, 1 year 4 months ago High Demand and Attractive Pricing: CHEPLAPHARM's New 7.125% Bond Multiple Times Oversubscribed CHEPLAPHARM successfully places €750m senior secured notes at 7.125% interest rate, enhancing financial flexibility and extending maturity profile, oversubscribed transaction Senior Secured Notes Oversubscribed Financial Flexibility CHEPLAPHARM 7.125%
BRIEF published on 06/02/2025 at 10:34, 1 year 5 months ago Sandra Schröder Joins CHEPLAPHARM as VP Scientific Pharmaceutical Regulatory Affairs Quality Management CHEPLAPHARM Sandra Schröder
PRESS RELEASE published on 06/02/2025 at 10:29, 1 year 5 months ago Sandra Schröder joins CHEPLAPHARM’S Management Team as VP Scientific Sandra Schröder appointed as VP Scientific at CHEPLAPHARM, responsible for scientific areas globally. Brings 25 years of experience from F. Hoffmann-La Roche AG Pharmaceutical Industry Management CHEPLAPHARM Sandra Schröder VP Scientific
BRIEF published on 01/02/2025 at 09:19, 1 year 10 months ago CHEPLAPHARM Appoints Tamás Szóga as VP Commercial Management Expansion CHEPLAPHARM Tamás Szóga VP Commercial Pharmaceutical Strategy
PRESS RELEASE published on 01/02/2025 at 09:14, 1 year 10 months ago CHEPLAPHARM expands Management with Tamás Szóga as VP Commercial CHEPLAPHARM expands management team by appointing Tamás Szóga as VP Commercial, responsible for strategic planning and development of Global Sales division Global Sales Strategic Planning CHEPLAPHARM Tamás Szóga VP Commercial
BRIEF published on 12/16/2024 at 08:53, 1 year 10 months ago CHEPLAPHARM Acquires Gemzar from Lilly Acquisition Oncology Eli Lilly CHEPLAPHARM Gemzar
PRESS RELEASE published on 12/16/2024 at 08:48, 1 year 10 months ago CHEPLAPHARM acquires Gemzar from Lilly CHEPLAPHARM acquires Gemzar from Lilly, expanding its oncology portfolio with a proven chemotherapeutic agent for various types of cancer Acquisition Oncology CHEPLAPHARM Chemotherapy Gemzar
Published on 11/06/2026 at 22:15, 6 hours 24 minutes ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 15 hours 39 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 16 hours 9 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 16 hours 9 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 20:15, 8 hours 24 minutes ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 19:15, 9 hours 24 minutes ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 9 hours 39 minutes ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 18:32, 10 hours 7 minutes ago EQS-Adhoc: Finexity AG: FINEXITY issues 2026/2030 bond
Published on 11/06/2026 at 18:00, 10 hours 39 minutes ago ARVERNE GROUP: Number shares and voting rights
Published on 11/06/2026 at 18:00, 10 hours 39 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 11/06/2026 at 17:54, 10 hours 45 minutes ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 11 hours 4 minutes ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
